BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Healthcare Master Fun Broadfin sold 2,000,000 shares of BioDelivery Sciences International stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $5.00, for a total transaction of $10,000,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of BDSI opened at $4.81 on Tuesday. The company has a market capitalization of $350.49 million, a PE ratio of -6.59 and a beta of 0.46. The company has a debt-to-equity ratio of 1.74, a quick ratio of 2.82 and a current ratio of 3.07. BioDelivery Sciences International, Inc. has a 12-month low of $1.70 and a 12-month high of $5.37.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Thursday, March 14th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.10). The company had revenue of $18.03 million for the quarter, compared to analysts’ expectations of $16.15 million. BioDelivery Sciences International had a negative net margin of 60.87% and a negative return on equity of 79.59%. As a group, research analysts forecast that BioDelivery Sciences International, Inc. will post -0.19 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in BDSI. Advisor Group Inc. increased its position in shares of BioDelivery Sciences International by 56.3% in the fourth quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock worth $40,000 after acquiring an additional 3,943 shares in the last quarter. Squarepoint Ops LLC purchased a new position in shares of BioDelivery Sciences International in the fourth quarter worth approximately $147,000. Raymond James & Associates increased its position in shares of BioDelivery Sciences International by 14.9% in the fourth quarter. Raymond James & Associates now owns 46,211 shares of the specialty pharmaceutical company’s stock worth $171,000 after acquiring an additional 6,000 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of BioDelivery Sciences International in the third quarter worth approximately $255,000. Finally, Virtu Financial LLC purchased a new position in shares of BioDelivery Sciences International in the first quarter worth approximately $300,000. 56.89% of the stock is currently owned by institutional investors.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Featured Story: Growth and Income Funds
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.